These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2651061)

  • 1. [Action profile of human ultralente insulin compared with human NPH-insulin].
    Starke AA; Heinemann L; Hohmann A; Berger M
    Dtsch Med Wochenschr; 1989 Apr; 114(16):618-22. PubMed ID: 2651061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Action profile of a semisynthetic human isophane zinc insulin compared with customary isophane insulin].
    Gin H; Delafaye C; Morlat P; Aubertin J
    Diabete Metab; 1992; 18(6):445-50. PubMed ID: 1297601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
    Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
    Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
    Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
    Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ultratard HM, a new human insulin. Advantages as compared to current preparations?].
    Saner B; Fankhauser S
    Schweiz Med Wochenschr; 1986 Jan; 116(4):116-9. PubMed ID: 3513303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.
    Sørensen LP; Brock B; Mengel A; Rungby J; Moller N; Nielsen S; Vølund A; Schmitz O
    Diabet Med; 2010 Jul; 27(7):830-7. PubMed ID: 20636965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the pharmacokinetics of human protamine sodium insulin with human isophane insulin following subcutaneous injection in normal subjects.
    Burke B; Andrews WJ; Hadden DR
    Diabetes Res; 1987 Apr; 4(4):163-7. PubMed ID: 3304782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
    Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
    Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study.
    Cernea S; Kidron M; Wohlgelernter J; Raz I
    Clin Ther; 2005 Oct; 27(10):1562-70. PubMed ID: 16330292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-action profile of inhaled insulin.
    Heinemann L; Traut T; Heise T
    Diabet Med; 1997 Jan; 14(1):63-72. PubMed ID: 9017356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans.
    Brunner GA; Sendhofer G; Wutte A; Ellmerer M; Søgaard B; Siebenhofer A; Hirschberger S; Krejs GJ; Pieber TR
    Exp Clin Endocrinol Diabetes; 2000; 108(2):100-5. PubMed ID: 10826516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Action of a semi-synthetic human insulin preparation (30/70 NPH insulin Organon): comparison with another 30/70 NPH (Actraphane Novo).
    Gin H; Nivet AM; Morlat P; Aubertin J
    Diabete Metab; 1989; 15(5):247-50. PubMed ID: 2698366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Action profile of biosynthetic human proinsulin trials with the BIOSTATOR in metabolically normal subjects.
    Bottermann P; Wahl K; Ermler R; Gray IP; Hales CN
    Horm Metab Res Suppl; 1988; 18():6-11. PubMed ID: 3056813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-action profiles of the intermediate-acting insulin analogue des(64,65)-human proinsulin.
    Heinemann L; Heise T; Klepper A; Ampudia J; Bender R; Starke AA
    Diabete Metab; 1995 Dec; 21(6):415-9. PubMed ID: 8593922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical strategies for controlling peaks and valleys: type 1 diabetes.
    Bolli GB
    Int J Clin Pract Suppl; 2002 Jul; (129):65-74. PubMed ID: 12166610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes.
    Luzio SD; Beck P; Owens DR
    Horm Metab Res; 2003 Jul; 35(7):434-8. PubMed ID: 12931275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption kinetics and action profiles of intermediate acting human insulins.
    Bilo HJ; Heine RJ; Sikkenk AC; van der Meer J; van der Veen EA
    Diabetes Res; 1987 Jan; 4(1):39-43. PubMed ID: 3552366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two ultralente insulin preparations with protamine zinc insulin in clinically normal cats.
    Broussard JD; Peterson ME
    Am J Vet Res; 1994 Jan; 55(1):127-31. PubMed ID: 8141485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physico-chemical properties of insulin and physiological factors.
    Hildebrandt P
    Dan Med Bull; 1991 Aug; 38(4):337-46. PubMed ID: 1914533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue.
    Jørgensen S; Vaag A; Langkjaer L; Hougaard P; Markussen J
    BMJ; 1989 Aug; 299(6696):415-9. PubMed ID: 2506998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.